TRVN: חוב כולל להון Trevena

Trevena, Inc. (TRVN) is currently in a lull due to low demand for the drug Olinvyk, forcing management to implement strict cost-cutting measures. This price chart reflects a debt-to-equity ratio of 0.00. The company develops unique CNS treatments using the biased ligand method to combat pain without the risk of addiction. However, leadership at this micro-cap biotech is facing a capital shortage and regulatory challenges.

The virtual model of Trevena, Inc. (TRVN), which delegates trials to external CROs, minimizes capital expenditures, directly impacting the balance sheet structure. By analyzing changes in the debt-to-equity ratio, investors assess the proportion of total liabilities relative to shareholders' equity: a decrease in this ratio confirms crisis resilience, whereas an increase signals heightened debt leverage and credit risks.